Inhaled alpha 1-antitrypsin: Gauging patient interest in a new treatment

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 4, 2013, Pages 411-415

  Monk, Richard ^a   Graves, Michael ^a   Williams, Pamela ^b   Strange, Charlie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aerosol; Augmentation; Emphysema; Patient preference; Serpin

Indexed keywords

ALPHA 1 ANTITRYPSIN; BRONCHODILATING AGENT; CORTICOSTEROID;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG COST; DRUG DELIVERY DEVICE; DRUG DOSAGE FORM COMPARISON; DRUG USE; E-MAIL; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NEBULIZER; PATIENT ATTITUDE; PATIENT PREFERENCE; POWDER INHALER; PRIORITY JOURNAL; REGISTER; SELF REPORT; SUBSTITUTION THERAPY;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DRY POWDER INHALERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT PREFERENCE; QUESTIONNAIRES; TRYPSIN INHIBITORS;

EID: 84880752065     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.758698     Document Type: Article

References (25)

1. American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7):818-900.
2. Kropp J, Wencker M, Hotze A, et al. Inhalation of [123I] alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med 2001; 42(5):744-751.
3. Meyer T, Müllinger B, Sommerer K, et al. Pulmonary deposition of monodisperse aerosols in patients with chronic obstructive pulmonary disease. Exp Lung Res 2003; 29(7):475-484.
4. Brand P, Schulte M, Wencker M, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009; 34(2):354-360.
5. Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990; 168 Suppl:565-578.
6. Siekmeier R. Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI)-problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis. Eur J Med Res 2010; 15 Suppl 2:164-174.
7. International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema. ClinicalTrials. gov. http://clinicaltrials.gov/ct2/show/NCT01217671? term= nct01217671&rank=1. Accessed August 20, 2012.
8. Brand P, Beckmann H, Maas-Enriquez M, et al. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22(2):263-267.
9. Hubbard RC, Casolaro MA, Mitchell M, et al. Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc Natl Acad Sci USA 1989; 86(2):680-684.
10. Smith RM, Traber LD, Traber DL, Spragg RG. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. J Clin Invest 1989; 84(4):1145-1154.
11. Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitryspin deficiency. J Clin Invest 1989; 84(4):1349-1354.
12. Griese M, von Bredow C, Birrer P. Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fl uid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis. Electrophoresis 2001;22(1):165-171.
13. Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006; 29(4):201-207.
14. Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 1989; 111(3):206-212.
15. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337(8738):392-394.
16. Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway infl ammation in cystic fibrosis patients. Eur Respir J 2007; 29(2):240-250.
17. Vogelmeier C, Kirlath I, Warrington S, Banik N, Ulbrich E, Du Bois RM. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997; 155(2):536-541.
18. Smith RM, Spragg RG, Moser KM. Biologic availability of injected or aerosolized alpha 1 proteinase inhibitor. Prog Clin Biol Res 1987; 236A:203-210.
19. Cape SP, Villa JA, Huang ET, Yang TH, Carpenter JF, Sievers RE. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fl uids. Pharm Res 2008; 25(9):1967-990.
20. Geller DE, Kesser KC. The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Deliv 2010; 23 Suppl 1:S55-S59.
21. Alpha-1 Foundation Research Registry. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00499941?term=nct00 499941&rank=1. Accessed August 20, 2012.
22. 1-antitrypsin deficiency. Eur Respir J 2005; 25(6):992-1000.
23. 1- antitrypsin. Am J Respir Crit Care Med 1998; 158(1):49-59.
24. th Meeting, July 20-21, 2009. http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/bloodvaccinesandotherbiologics/bloodproductsadvisory committee/ucm171091.pdf. Accessed July 10, 2012.
25. Pierce JA. Antitrypsin and emphysema: perspective and prospects. JAMA 1988; 259(19):2890-2895.